Division of Cancer Genomics, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Br J Cancer. 2011 Jun 28;105(1):131-8. doi: 10.1038/bjc.2011.199. Epub 2011 Jun 14.
Cholangiocarcinoma (CC) is a highly malignant carcinoma. We attempted to clarify the prognostic significance of c-Met overexpression and its association with clinicopathological factors in patients with CC.
One hundred and eleven patients with intrahepatic CC (IHCC) and 136 patients with extrahepatic CC (EHCC) who had undergone curative surgery were divided immunohistologically into c-Met(high) and c-Met(low) groups. Clinicopathological factors and outcomes were compared between the groups. c-Met and epidermal growth factor receptor (EGFR) expression was also examined in 10 CC cell lines.
The positivity of c-Met was 45.0% in IHCC and 68.4% in EHCC; c-Met(high) expression was demonstrated in 11.7% of IHCC and 16.2% of EHCC. c-Met(high) expression was significantly correlated with the 5-year survival rate for CC overall (P=0.0046) and for IHCC (P=0.0013), histopathological classification in EHCC, and for EGFR overexpression in both IHCC and EHCC. Coexpression and coactivation of c-Met and EGFR were also observed in CC cell lines. Multivariate analysis revealed that c-Met(high) expression was an independent predictor of poor overall and disease-free survival in patients with IHCC.
c-Met overexpression is associated with EGFR expression and is a poor prognostic factor in CC.
胆管癌（CC）是一种高度恶性的癌。我们试图阐明 c-Met 过表达的预后意义及其与 CC 患者临床病理因素的关系。
111 例肝内胆管癌（IHCC）和 136 例肝外胆管癌（EHCC）患者经手术根治性切除，免疫组织化学方法将其分为 c-Met（高）和 c-Met（低）组。比较两组的临床病理因素和结局。还检测了 10 种 CC 细胞系中 c-Met 和表皮生长因子受体（EGFR）的表达。
IHCC 中 c-Met 的阳性率为 45.0%，EHCC 为 68.4%；IHCC 中 c-Met（高）表达率为 11.7%，EHCC 为 16.2%。c-Met（高）表达与 CC 总生存率（P=0.0046）和 IHCC 生存率（P=0.0013）、EHCC 的组织病理学分类以及 IHCC 和 EHCC 中 EGFR 过表达显著相关。还观察到 CC 细胞系中 c-Met 和 EGFR 的共表达和共激活。多因素分析显示，c-Met（高）表达是 IHCC 患者总生存和无病生存的独立预后因素。
c-Met 过表达与 EGFR 表达相关，是 CC 的不良预后因素。
